HA is commonly used for the targeting of tumour cells because of its affinity to target particular over-expressed cell receptors—mainly to the cell surface receptors called hyaladherins, such as clusters of differentiation, commonly cluster of differentiation 44 (CD44+) as well as 36 (CD36), protein phosphatase 2 (PP2A), cyclin dependant kinase 9 (CDK9) [6], a receptor for hyaluronate-mediated mortality (RHAMM) [7], lymphatic vessel endothelial HA receptor (LYVE-1) [8], and tumour necrosis factor-stimulated gene-6 (TSG-6) [9,10]. This evidence concerns the gene CDK9 and neoplasm.